Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2018 2
2019 2
2020 3
2021 4
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H, Georgiadis S, Loft AG, Hendricks O, Jensen DV, Andersen M, Chrysidis S, Colic A, Danebod K, Hussein MR, Kalisz MH, Kristensen S, Lomborg N, Manilo N, Munk HL, Pedersen JK, Raun JL, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Nabi H, et al. Among authors: danebod k. Ann Rheum Dis. 2021 Nov;80(11):1400-1409. doi: 10.1136/annrheumdis-2021-219951. Epub 2021 Apr 29. Ann Rheum Dis. 2021. PMID: 33926921
Anxiety and concerns related to the work situation during the second wave of the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the DANBIO registry.
Glintborg B, Jensen DV, Engel S, Terslev L, Pfeiffer Jensen M, Hendricks O, Østergaard M, Horskjær Rasmussen S, Adelsten T, Colic A, Danebod K, Kildemand M, Loft AG, Munk HL, Pedersen JK, Østgård RD, Møller Sørensen C, Krogh NS, Nørgaard Agerbo J, Ziegler C, Lund Hetland M. Glintborg B, et al. Among authors: danebod k. RMD Open. 2021 May;7(2):e001649. doi: 10.1136/rmdopen-2021-001649. RMD Open. 2021. PMID: 33941664 Free PMC article. No abstract available.
Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis.
Glintborg B, Jensen DV, Terslev L, Pfeiffer Jensen M, Hendricks O, Østergaard M, Engel S, Horskjær Rasmussen S, Adelsten T, Colic A, Danebod K, Kildemand M, Loft AG, Munk HL, Pedersen JK, Østgård RD, Møller Sørensen C, Krogh NS, Nørgaard Agerbo J, Ziegler C, Hetland ML. Glintborg B, et al. Among authors: danebod k. Rheumatology (Oxford). 2021 Oct 9;60(SI):SI3-SI12. doi: 10.1093/rheumatology/keab500. Rheumatology (Oxford). 2021. PMID: 34146099 Free PMC article.
Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry.
Glintborg B, Jensen DV, Engel S, Terslev L, Pfeiffer Jensen M, Hendricks O, Ostergaard M, Horskjær Rasmussen S, Adelsten T, Colic A, Danebod K, Kildemand M, Loft AG, Munk HL, Pedersen JK, Østgård RD, Møller Sørensen C, Krogh NS, Agerbo J, Ziegler C, Hetland M. Glintborg B, et al. Among authors: danebod k. RMD Open. 2021 Jan;7(1):e001505. doi: 10.1136/rmdopen-2020-001505. RMD Open. 2021. PMID: 33402443 Free PMC article.
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Pedersen DD, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Lund Hetland M. Glintborg B, et al. Among authors: danebod k. Ann Rheum Dis. 2020 Apr;79(4):e37. doi: 10.1136/annrheumdis-2018-214952. Epub 2019 Jan 23. Ann Rheum Dis. 2020. PMID: 30674476 No abstract available.
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: danebod k. Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20. Ann Rheum Dis. 2020. PMID: 30573653 No abstract available.
Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.
Glintborg B, Georgiadis S, Loft AG, Linauskas A, Lindegaard H, Hendricks O, Jensen DV, Andersen BL, Danebod K, Villumsen A, Eng G, Wiell C, Manilo N, Kristensen S, Raun J, Grydehøj J, Chrysidis S, Nørgaard M, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: danebod k. Ann Rheum Dis. 2020 Jun;79(6):846-848. doi: 10.1136/annrheumdis-2019-216702. Epub 2020 Feb 28. Ann Rheum Dis. 2020. PMID: 32111583 No abstract available.
Long-term Behavioral Changes During the COVID-19 Pandemic and Impact of Vaccination in Patients With Inflammatory Rheumatic Diseases.
Glintborg B, Jensen DV, Terslev L, Hendricks O, Østergaard M, Rasmussen SH, Jensen MP, Adelsten T, Colic A, Danebod K, Kildemand M, Loft AG, Munk HL, Pedersen JK, Østgård RD, Sørensen CM, Krogh NS, Agerbo JN, Ziegler C, Hetland ML. Glintborg B, et al. Among authors: danebod k. J Rheumatol. 2022 Oct;49(10):1163-1172. doi: 10.3899/jrheum.211280. Epub 2022 Jun 15. J Rheumatol. 2022. PMID: 35705237 Free article.
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, Danebod K, Jensen DV, Nordin H, Dalgaard EB, Chrysidis S, Kristensen S, Raun JL, Lindegaard H, Manilo N, Jakobsen SH, Hansen IMJ, Dalsgaard Pedersen D, Sørensen IJ, Andersen LS, Grydehøj J, Mehnert F, Krogh NS, Hetland ML. Glintborg B, et al. Among authors: danebod k. Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5. Ann Rheum Dis. 2019. PMID: 30396903
Thymus size at 6 months of age and subsequent child mortality.
Garly ML, Trautner SL, Marx C, Danebod K, Nielsen J, Ravn H, Martins CL, Balé C, Aaby P, Lisse IM. Garly ML, et al. Among authors: danebod k. J Pediatr. 2008 Nov;153(5):683-8, 688.e1-3. doi: 10.1016/j.jpeds.2008.04.069. Epub 2008 Jun 27. J Pediatr. 2008. PMID: 18589444 Clinical Trial.
12 results